151 results
8-K
AGRX
Agile Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
8:30am
materials (the “Secured Obligations”), Agile granted Corium a lien in the Company’s inventory up to the value of the Secured Obligations (“Secured Lien
8-K
ecociw64g
25 Mar 24
Agile Therapeutics Announces Delisting from Nasdaq
4:30pm
8-K
EX-10.1
tp972o
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
qeeaq
15 Feb 24
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
4:45pm
8-K
uvaxpdw6bxe
6 Dec 23
Other Events
8:00am
8-K
EX-10.1
0zv7rko
4 Dec 23
Entry into a Material Definitive Agreement
8:00am
8-K
ep993
2 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-10.1
r1pfp vkk
28 Sep 23
Entry into a Material Definitive Agreement
4:50pm